Phosphotyrosyl mimetics in the development of signal transduction inhibitors

Accounts of Chemical Research

Volumn 36, Issue 6, 2003, Pages 426-433

  Burke Jr , Terrence R ^a   Lee, Kyeong ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Ewha Womans University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ORGANOPHOSPHATE; PHOSPHOTYROSINE; PROTEIN TYROSINE KINASE INHIBITOR;

BIOAVAILABILITY; DRUG STRUCTURE; ENZYME ACTIVE SITE; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

BINDING SITES; DRUG DESIGN; MOLECULAR MIMICRY; PHOSPHORUS; PHOSPHOTYROSINE; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS;

EID: 0038679457     PISSN: 00014842     EISSN: None     Source Type: Journal    
DOI: 10.1021/ar020127o     Document Type: Review

References (84)

1. Hunter, T. Signaling - 2000 and beyond. Cell 2000, 100, 113-127.
2. Panayotou, G.; Waterfield, M. D. The assembly of signaling complexes by receptor tyrosine kinases. Bioessays 1993, 15, 171-177.
3. Leof, E. B. Growth factor receptor signaling: location, location, location. Trends Cell Biol. 2000, 10, 343-348.
4. Pawson, T.; Raina, M.; Nash, P. Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett. 2002, 513, 2-10.
5. Ostman, A.; Bohmer, F. D. Regulation of receptor tyrosine kinase signaling by protein tyrosine phosphatases. Trends Cell Biol. 2001, 11, 258-266.
6. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signaling. Nature 2001, 411, 355-365.
7. Cohen, P. The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3, 459-465.
8. Levitzki, A. Protein tyrosine kinase inhibitors as therapeutic agents. Top. Curr. Chem. 2001, 211, 1-15.
9. Shawver, L. K.; Slamon, D.; Ullrich, A. Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002, 1, 117-123.
10. Burke, T. R., Jr.; Yao, Z.-J.; Smyth, M. S.; Ye, B. Phosphotyrosyl-based motifs in the structure-based design of protein-tyrosine kinase-dependent signal transduction inhibitors. Curr. Pharm. Des. 1997, 3, 291-304.
11. Burke, T. R., Jr.; Gao, Y.; Yao, Z.-J. Phosphoryltyrosyl mimetics as signaling modulators and potential antitumor agents. Biomedical Chemistry: Applying Chemical Principles to the Understanding and Treatment of Disease, 1st ed.; John Wiley & Sons: New York, 2000; pp 189-210.
12. Burke, T. R., Jr.; Yao, Z.-J.; Liu, D.-G.; Voigt, J.; Gao, Y. Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers 2001, 60, 32-44.
13. Morin, M. J. From oncogene to drug: Development of small molecule tyrosine kinase inhibitors as antitumor and antiangiogenic agents. Oncogene 2000, 19, 6574-6583.
14. Traxler, P,; Bold, G.; Buchdunger, E.; Caravatti, G.; Furet, P.; Manley, P.; O'Reilly, T.; Wood, J.; Zimmermann, J. Tyrosine kinase inhibitors: From rational design to clinical trials. Med. Res. Rev. 2001, 21, 499-512.
15. Peterli, S.; Hubmann, D.; Sequin, U.; Mett, H.; Traxler, P. Nitrostyrene derivatives of adenosine 5′-glutarates modified with an alkyl spacer and their inhibitory activity on epidermal growth factor receptor protein tyrosine kinase. Helv. Chim. Acta 1994, 77, 59-69.
16. Traxler, P. M.; Wacker, O.; Bach, H. L.; Geissler, J. F.; Kump, W.; Meyer, T.; Regenass, U.; Roesel, J. L.; Lydon, N. Sulfonylbenzoyl nitrostyrenes - potential bisubstrate type inhibitors of the EGF-receptor tyrosine protein kinase. J. Med, Chem. 1991, 34, 2328-2337.
17. Saperstein, R.; Vicario, P. P.; Strout, H. V.; Brady, E.; Slater, E. E.; Greenlee, W. J.; Ondeyka, D. L.; Patchett, A. A.; Hangauer, D. G. Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells. Biochemistry 1989, 28, 5694-5701.
18. Burke, T. R., Jr.; Li, Z. H.; Bolen, J. B.; Marquez, V. E. Phosphonate-containing inhibitors of tyrosine-specific protein kinases. J. Med. Chem. 1991, 34, 1577-1581.
19. Marsilje, T. H.; Milkiewicz, K. L.; Hangauer, D. G. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(C-src) tyrosine kinase. Part 1: Hydroxynaphthalene derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 477-481.
20. Milkiewicz, K. L.; Marsilje, T. H.; Woodworth, R. P.; Bifulco, N.; Hangauer, M. J.; Hangauer, D. G. The design, synthesis and activity of non-ATP competitive inhibitors of pp60(C-src) tyrosine kinase. Part 2: Hydroxyindole derivatives. Bioorg. Med. Chem. Lett. 2000, 10, 483-486.
21. Songyang, Z. Recognition and regulation of primary-sequence motifs by signaling modular domains. Prog. Biophys. Mol. Biol. 1999, 71, 359-372,
22. Songyang, Z.; Shoelson, S. E.; Chaudhuri, M.; Gish, G.; Pawson, T.; Haser, W. G.; King, F.; Roberts, T.; Ratnofsky, S.; Lechleider, R. J.; Neel, B. G.; Birge, R. B.; Fajardo, J. E.; Chou, M. M.; Hanafusa, H.; Schaffhausen, B.; Cantley, L. C. SH2 domains recognize specific phosphopeptide sequences. Cell 1993, 72, 767-778.
23. Eck, M. J.; Shoelson, S. E.; Harrison, S. C. Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56(lck). Nature 1993, 362, 87-91.
24. Umezawa, Y.; Nishio, M. CH/pi Interactions as demonstrated in the cyrstal structure of guanine-nucleotide binding proteins, Src homology 2 domains and human growth hormone in complex with their specific ligands. Bioorg. Med. Chem. 1998, 6, 493-504.
25. Rahuel, J.; Gay, B.; Erdmann, D.; Strauss, A.; GarciaEcheverria, C.; Furet, P.; Caravatti, G.; Fretz, H.; Schoepfer, J.; Grutter, M. G. Structural basis for specificity of Grb2-SH2 revealed by a novel ligand binding mode. Nat. Struct. Biol. 1996, 3, 586-589.
26. Grucza, R. A.; Bradshaw, J. M.; Futterer, K.; Waksman, G. SH2 domains: From structure to energetics, a dual approach to the study of structure-function relationships. Med. Res. Rev. 1999, 19, 273-293.
27. Lemmon, M. A.; Ladbury, J. E. Thermodynamic studies of tyrosylphosphopeptide binding to the SH2 domain of p56(Lck). Biochemistry 1994, 33, 5070-5076.
28. Muller, G. Peptidomimetic SH2 domain antagonists for targeting signal transduction. Top. Curr. Chem. 2001, 211, 17-59.
29. Garcia-Echeverria, C. Antagonists of the Src homology 2 (SH2) domains of Grb2, Src, Lck and ZAP-70. Curr. Med. Chem. 2001, 8, 1589-1604.
30. Sawyer, T. K.; Bohacek, R. S.; Dalgarno, D. C.; Eyermann, C. J.; Kawahata, N.; Metcalf, C. A., III.; Shakespeare, W. C.; Sundaramoorthi, R.; Wang, Y.; Yang, M, G. Src homology-2 inhibitors: Peptidomimetic and nonpeptide. Mini-Rev. Med. Chem. 2002, 2, 475-489.
31. Siegal, G. The surprisingly flexible PTB domain. Nat. Struct. Biol. 1999, 6, 7-10.
32. Margolis, B. L. Function of PTB domain proteins. FASEB J. 1999, 13, A1422.
33. Yan, K. S.; Kuti, M.; Zhou, M.-M. PTB or not PTB - that is the question. FEBS Lett. 2002, 513, 67-70.
34. Zhou, M. M.; Ravichandran, K. S.; Olejniczak, E. T.; Petros, A. M.; Meadows, R. P.; Sattler, M.; Harlan, J. E.; Wade, W. S.; Burakoff, S. J.; Fesik, S. W. Structure and ligand recognition of the phosphotyrosine binding domain of Shc. Nature 1995, 378, 584-592.
35. Bradshaw, J. M.; Mitaxov, V.; Waksman, G. Investigation of phosphotyrosine recognition by the SH2 domain of the Src kinase. J. Mol. Biol. 1999, 293, 971-985.
36. Wishart, M. J.; Dixon, J. E. Gathering STYX: phosphatase like form predicts functions for unique protein-interaction domains. Trends Biochem. Sci. 1998, 23, 301-306.
37. Khandelwal, P.; Keliikuli, K.; Smith, C. L.; Saper, M. A.; Zuiderweg, E. R. P. Solution structure and phosphopeptide binding to the N-terminal domain of Yersinia YopH: Comparison with a crystal structure. Biochemistry (in press).
38. Barford, D.; Das, A. K.; Egloff, M. P. The structure and mechanism of protein phosphatases: Insights into catalysis and regulation. Annu. Rev. Biophys. Biomol. Struct. 1998, 27, 133-164.
39. Burke, T. R.; Zhang, Z. Y. Protein-tyrosine phosphatases: Structure, mechanism, and inhibitor discovery. Biopolymers 1998, 47, 225-241.
40. Zhang, Z.-Y. Protein tyrosine phosphatases: structure and function, substrate specificity, and inhibitor development. Annu. Rev. Pharm. Tox. 2002, 42, 209-234.
41. Marseigne, I.; Roques, B. P. Synthesis of new amino acids mimicking sulfated and phosphorylated tyrosine residues. J. Org. Chem. 1988, 53, 3621-3624.
42. Burke, T. R., Jr.; Russ, P.; Lim, B. Preparation of 4-[bis(tert-butyl)phosphonomethyl]-N-Fmoc-D,L-phenylalanine; a hydrolytically stable analogue of O-phosphotyrosine potentially suitable for peptide synthesis. Synthesis 1991, 11, 1019-1020.
43. Shoelson, S. E.; Chatterjee, S.; Chaudhuri, M.; Burke, T. R. Solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues with N(alpha)-Fmoc-(O,O-di-tert-butyl)phosphonopara-methylphenylalanine. Tetrahedron Lett. 1991, 32, 6061-6064.
44. Domchek, S. M.; Auger, K. R.; Chatterjee, S.; Burke, T. R.; Shoelson, S. E. Inhibition of SH2 domain/phosphoprotein association by a nonhydrolyzable phosphonopeptide. Biochemistry 1992, 31, 9865-9870.
45. Blackburn, G. M. Phosphonates as analogues of biological phosphates. Chem. Ind. (London) 1981, 134-138.
46. Blackburn, G. M.; Parratt, M. J. The synthesis of alpha-fluoro-alkylphosphonates. J. Chem. Soc., Chem. Commun. 1983, 886-888.
47. Smyth, M. S.; Ford, H., Jr.; Burke, T. R., Jr. A general method for the preparation of benzylic alpha, alpha-difluorophosphonic acids; non-hydrolyzable mimetics of phosphotyrosine. Tetrahedron Lett. 1992, 33, 4137-4140.
48. Burke, T. R.; Smyth, M. S.; Nomizu, M.; Otaka, A.; Roller, P. P. Preparation of fluoro-4-(phosphonomethl)-D,L-phenylalanine and hydroxy-4-(phosphonomethyl)-D,L-phenylalanine suitably protected for solid-phase synthesis of peptides containing hydrolytically stable analogues of O-phosphotyrosine. J. Org. Chem. 1993, 58, 1336-1340.
49. Burke, T. R., Jr.; Smyth, M. S.; Otaka, A.; Nomizu, M.; Roller, P. P.; Wolf, G,; Case, R.; Shoelson, S. E. Nonhydrolyzable phosphotyrosyl mimetics for the preparation of phosphatase-resistant SH2 domain inhibitors. Biochemistry 1994, 33, 6490-6494.
50. Giorgetti-Peraldi, S.; Ottinger, E.; Wolf, G.; Ye, B.; Burke, T. R., Jr.; Shoelson, S. E. Cellular effects of phosphotyrosine-binding domain inhibitors on insulin receptor signaling and trafficking. Mol. Cell. Biol. 1997, 17, 1180-1188.
51. Burke, T. R.; Kole, H. K.; Roller, P. P. Potent inhibition of insulin receptor dephosphorylation by a hexamer peptide containing the phosphotyrosyl mimetic F(2)Pmp. Biochem. Biophys. Res. Commun. 1994, 204, 129-134.
52. Chen, L.; Wu, L.; Otaka, A.; Smyth, M. S.; Roller, P. P.; Burke, T. R.; Denhertog, J.; Zhang, Z. Y. Why is phosphonodifluoromethyl phenylalanine a more potent inhibitory moiety than phosphonomethyl phenylalanine toward protein-tyrosine phosphatases? Biochem, Biophys. Res. Commun. 1995, 216, 976-984.
53. Burke, T. R.; Ye, B.; Yan, X. J.; Wang, S. M.; Jia, Z. C.; Chen, L.; Zhang, Z. Y.; Barford, D. Small molecule interactions with proteintyrosine phosphatase PTP1B and their use in inhibitor design. Biochemistry 1996, 35, 15989-15996.
54. Groves, M. R.; Yao, Z. J.; Roller, P. P.; Burke, T. R.; Barford, D. Structural basis for inhibition of the protein tyrosine phosphatase 1B by phosphotyrosine peptide mimetics. Biochemistry 1998, 37, 17773-17783.
55. Kotoris, C. C.; Wen, W.; Lough, A.; Taylor, S. D. Preparation of chiral alpha-monofluoroalkylphosphonic acids and their evaluation as inhibitors of protein tyrosine phosphatase 1B. J. Chem. Soc., Perkin Trans. 1 2000, 8, 1271-1281.
56. Burke, T. R.; Smyth, M. S.; Otaka, A.; Roller, P. P. Synthesis of 4-phosphono(difluoromethyl)-D,L-phenylalanine and N-Boc and N-Fmoc derivatives suitably protected for solid-phase synthesis of nonhydrolyzable phosphotyrosyl peptide analogues. Tetrahedron Lett. 1993, 34, 4125-4128.
57. Wrobel, J.; Dietrich, A. Preparation of L-(phosphonodifluoromethyl)phenylalanine derivatives as non-hydrolyzable mimetics of O-phosphotyrosine. Tetrahedron Lett 1993, 34, 3543-3546.
58. Smyth, M. S.; Burke, T. R., Jr. Enantioselective synthesis of N-Boc and N-Fmoc protected diethyl 4-phosphonodifluoromethyl-L-phenylalanine; agents suitable for the solid-phase synthesis of peptides containing nonhydrolyzable analogues of O-phosphotyrosine. Tetrahedron Lett. 1994, 35, 551-554.
59. Solas, D.; Hale, R. L.; Patel, D. V. An efficient synthesis of N-alpha-Fmoc-4-(phosphonodifluoromethyl)-L-phenylalanine. J. Org. Chem. 1996, 61, 1537-1539.
60. 2) derivatives. Tetrahedron 1997, 53, 11171-11178.
61. Stankovic, C. J.; Surendran, N.; Lunney, E. A.; Plummer, M. S.; Para, K. S.; Shahripour, A.; Fergus, J. H.; Marks, J. S.; Herrera, R.; Hubbell, S. E.; Humblet, C.; Saltiel, A. R.; Stewart, B. H.; Sawyer, T. K. The role of 4-phosphonodifluoromethyl- and 4-phosphono-phenylalanine in the selectivity and cellular uptake of SH2 domain ligands. Bioorg. Med. Chem. Lett. 1997, 7, 1909-1914.
62. Walker, C. V.; Caravatti, G.; Denholm, A. A.; Egerton, J.; Faessler, A.; Furet, P.; GarciaEcheverria, C.; Gay, B.; Irving, E.; Jones, K.; Lambert, A.; Press, N. J.; Woods, J. Structure-based design and synthesis of phosphinate isosteres of phosphotyrosine for incorporation in Grb2-SH2 domain inhibitors. Part 2. Bioorg. Med. Chem. Lett. 2000, 10, 2343-2346,
63. Shakespeare, W. C.; Bohacek, R. S.; Narula, S. S.; Azimioara, M. D.; Yuan, R. W.; Dalgarno, D. C.; Madden, L.; Botfield, M. C.; Holt, D. A. An efficient synthesis of a 4′-phosphonodifluoromethyl-3′-formyl-phenylalanine containing Src SH2 ligand. Bioorg. Med. Chem. Lett. 1999, 9, 3109-3112,
64. Shakespeare, W.; Yang, M.; Bohacek, R.; Cerasoli, F.; Stebbins, K.; Sundaramoorthi, R.; Azimioara, M.; Vu, C.; Selvi Pradeepan; Chester Metcalf, I.; Haraldson, C.; Merry, T.; Dalgarno, D.; Narula, S.; Hatada, M.; Lu, X.; van Schravendijk, M. R.; Adams, S.; Violette, S.; Smith, J.; Guan, W.; Bartlett, C.; Herson, J.; Iuliucci, J.; Weigele, M.; Sawyer, T. Structure-based design of an osteoclast-selective, nonpeptide Src homology 2 inhibitor with in vivo antiresorptive activity. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9373-9378.
65. Bohacek, R. S.; Dalgarno, D. C.; Hatada, M.; Jacobsen, V. A.; Lynch, B. A.; Macek, K. J.; Merry, T.; Metcalf, C. A.; Narula, S. S.; Sawyer, T. K.; Shakespeare, W. C.; Violette, S. M.; Weigele, M. X-ray structure of citrate bound to Src SH2 leads to a high-affinity, bone-targeted Src SH2 inhibitor. J. Med. Chem. 2001, 44, 660-663.
66. Gay, B.; Suarez, S.; Caravatti, G.; Furet, P.; Meyer, T.; Schoepfer, J. Selective Grb2 SH2 inhibitors as anti-Ras therapy. Int. J. Cancer 1999, 83, 235-241.
67. Kole, H. K.; Ye, B.; Akamatsu, M.; Yan, X.; Barford, D.; Roller, P. P.; Burke, T. R., Jr. Protein-tyrosine phosphatase inhibition by a peptide containing the phosphotyrosyl mimetic, O-malonyl-tyrosine (OMT). Biochem. Biophys. Res. Commun. 1995, 209, 817-822.
68. Ye, B.; Akamatsu, M.; Shoelson, S. E.; Wolf, G.; Giorgetti-Peraldi, S.; Yan, X. J.; Roller, P. P.; Burke, T. R. L-O-(2-malonyl)tyrosine: A new phosphotyrosyl mimetic for the preparation of Src homology 2 domain inhibitory peptides. J. Med. Chem. 1995, 38, 4270-4275.
69. Burke, T. R.; Ye, B.; Akamatsu, M.; Ford, H.; Yan, X. J.; Kole, H. K.; Wolf, G.; Shoelson, S. E.; Roller, P. P. 4′-O-[2-(2-fluoromalonyl)]-L-tyrosine: A phosphotyrosyl mimic for the preparation of signal transduction inhibitory peptides. J. Med. Chem. 1996, 39, 1021-1027.
70. Gao, Y.; Burke, T. R., Jr. Stereoselective preparation of 4-(2′-malonyl)phenylalanine suitably protected for Fmoc-based synthesis of potent signal transduction inhibitor ligands. Synlet 2000, 134-136.
71. Gao, Y.; Luo, J.; Yao, Z.-J.; Guo, R.; Zou, H.; Kelley, J.; Voigt, J. H.; Yang, D.; Burke, T. R., Jr. Inhibition of Grb2 SH2 domain binding by nonphosphate containing ligands 2. 4-(2-Malonyl)phenylalanine as a potent phosphotyrosyl mimetic. J. Med. Chem. 2000, 43, 911-920.
72. Gao, Y.; Wu, L.; Luo, J. H.; Guo, R.; Yang, D.; Zhang, Z.-Y.; Burke, T. R., Jr. Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains. Bioorg. Med. Chem. Lett. 2000, 10, 923-927.
73. Burke, T. R.; Yao, Z. J.; Zhao, H.; Milne, G. W. A.; Wu, L.; Zhang, Z. Y.; Voigt, J. H. Enantioselective synthesis of nonphosphorus-containing phosphotyrosyl mimetics and their use in the preparation of tyrosine phosphatase inhibitory peptides. Tetrahedron 1998, 54, 9981-9994.
74. Larsen, S. D.; Barf, T.; Liljebris, C.; May, P. D.; Ogg, D.; O'Sullivan, T. J.; Palazuk, B. J.; Schostarez, H. J.; Stevens, F. C.; Bleasdale, J. E. Synthesis and biological activity of a novel class of small molecular weight peptidomimetic competitive inhibitors of protein tyrosine phosphatase 1B. J. Med. Chem. 2002, 45, 598-622.
75. Yao, Z. J.; King, C. R.; Cao, T.; Kelley, J.; Milne, G. W. A.; Voigt, J. H.; Burke, T. R. Potent inhibition of Grb2 SH2 domain binding by non-phosphate-containing ligands. J. Med. Chem. 1999, 42, 25-35.
76. Lange, G.; Lesuisse, D.; Deprez, P.; Schoot, B.; Loenze, P.; Benard, D.; Marquette, J.-P.; Broto, P.; Sarubbi, E.; Mandine, E. Principles governing the binding of a class of non-peptidic inhibitors to the SH2 Domain of Src studied by X-ray analysis. J. Med. Chem. 2002, 45, 2915-2922.
77. Burke, T. R., Jr.; Luo, J.; Yao, Z.-J.; Gao, Y.; Milne, G. W. A.; Guo, R.; Voigt, J. H.; King, C. R.; Yang, D. Monocarboxylic phosphotyrosyl mimetics in the design of Grb2 SH2 domain inhibitors. Bioorg. Med. Chem. Lett. 1999, 9, 347-352.
78. Tong, L.; Warren, T. C.; Lukas, S.; SchembriKing, J.; Betageri, R.; Proudfoot, J. R.; Jakes, S. Carboxymethyl-phenylalanine as a replacement for phosphotyrosine in SH2 domain binding. J. Biol. Chem. 1998, 273, 20238-20242.
79. Beaulieu, P. L.; Cameron, D. R.; Ferland, J. M.; Gauthier, J.; Ghiro, E.; Gillard, J.; Gorys, V.; Poirier, M.; Rancourt, J.; Wernic, D.; LlinasBrunet, M.; Betageri, R.; Cardozo, M.; Hickey, E. R.; Ingraham, R.; Jakes, S.; Kabcenell, A.; Kirrane, T.; Lukas, S.; Patel, U.; Proudfoot, J.; Sharma, R.; Tong, L.; Moss, N. Ligands for the tyrosine kinase p56(Lck) SH2 domain: Discovery of potent dipeptide derivatives with monocharged, nonhydrolyzable phosphate replacements. J. Med. Chem. 1999, 42, 1757-1766.
80. Yao, Z. J.; Gao, Y.; Voigt, J. H.; Ford, H.; Burke, T. R. Synthesis of Fmoc-protected 4-carboxydifluoromethyl-L-phenylalanine: A phosphotyrosyl mimetic of potential use for signal transduction studies. Tetrahedron 1999, 55, 2865-2874.
81. Burke, T. R., Jr.; Barchi, J. J., Jr.; George, C.; Wolf, G.; Shoelson, S. E.; Yan, X. Conformationally constrained phosphotyrosyl mimetics designed as monomeric SH2 domain inhibitors. J. Med. Chem. 1995, 38, 1386-1396,
82. Wang, X.; Yao, Z. J.; Zhang, M.; Yang, D.; George, C.; Burke, T. R., Jr. Manuscript in preparation.
83. Davidson, J. P.; Martin, S. F. Use of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide mimics in SH2 antagonists. Tetrahedron Lett. 2000, 41, 9459-9464.
84. Davidson, J. P.; Lubman, O.; Rose, T.; Waksman, G.; Martin, S. F. Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding. J. Am. Chem. Soc. 2002, 124, 205-215.